These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37496455)

  • 21. Transcriptional benchmark dose modeling: Exploring how advances in chemical risk assessment may be applied to the radiation field.
    Chauhan V; Kuo B; McNamee JP; Wilkins RC; Yauk CL
    Environ Mol Mutagen; 2016 Oct; 57(8):589-604. PubMed ID: 27601323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the benchmark dose for point of departure determination for a variety of chemical classes in applied regulatory settings.
    Izadi H; Grundy JE; Bose R
    Risk Anal; 2012 May; 32(5):830-5. PubMed ID: 22126138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the lower limit of benchmark dose confidence interval with no-observed-adverse-effect level by applying four different software for tumorigenicity testing of pesticides in Japan.
    Yasuhiko Y; Ishigami M; Machino S; Fujii T; Aoki M; Irie F; Kanda Y; Yoshida M
    Regul Toxicol Pharmacol; 2022 Aug; 133():105201. PubMed ID: 35691450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD).
    Gaylor DW; Aylward LL
    Regul Toxicol Pharmacol; 2004 Aug; 40(1):9-17. PubMed ID: 15265602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current modeling practice may lead to falsely high benchmark dose estimates.
    Ringblom J; Johanson G; Öberg M
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):171-7. PubMed ID: 24662478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benchmark dose modelling in regulatory ecotoxicology, a potential tool in pest management.
    Jensen SM; Kluxen FM; Ritz C
    Pest Manag Sci; 2022 May; 78(5):1772-1779. PubMed ID: 34908226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benchmark dose calculation for ordered categorical responses.
    Chen CC; Chen JJ
    Risk Anal; 2014 Aug; 34(8):1435-47. PubMed ID: 24444309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of benchmark dose modeling to protein expression data in the development and analysis of mode of action/adverse outcome pathways for testicular toxicity.
    Chepelev NL; Meek ME; Yauk CL
    J Appl Toxicol; 2014 Nov; 34(11):1115-21. PubMed ID: 25244189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the influences of confounding variables on benchmark dose using a case study in the field of ionizing radiation.
    Adam N; Vuong NQ; Adams H; Kuo B; Beheshti A; Yauk C; Wilkins R; Chauhan V
    Int J Radiat Biol; 2022; 98(12):1845-1855. PubMed ID: 35939396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Properties of model-averaged BMDLs: a study of model averaging in dichotomous response risk estimation.
    Wheeler MW; Bailer AJ
    Risk Anal; 2007 Jun; 27(3):659-70. PubMed ID: 17640214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the assumption of normality or log-normality for continuous response data critical for benchmark dose estimation?
    Shao K; Gift JS; Setzer RW
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):767-79. PubMed ID: 23954464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benchmark dose profiles for joint-action quantal data in quantitative risk assessment.
    Deutsch RC; Piegorsch WW
    Biometrics; 2012 Dec; 68(4):1313-22. PubMed ID: 23278519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benchmark dose (BMD) modeling: current practice, issues, and challenges.
    Haber LT; Dourson ML; Allen BC; Hertzberg RC; Parker A; Vincent MJ; Maier A; Boobis AR
    Crit Rev Toxicol; 2018 May; 48(5):387-415. PubMed ID: 29516780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
    Davis JA; Gift JS; Zhao QJ
    Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BMDExpress Data Viewer - a visualization tool to analyze BMDExpress datasets.
    Kuo B; Francina Webster A; Thomas RS; Yauk CL
    J Appl Toxicol; 2016 Aug; 36(8):1048-59. PubMed ID: 26671443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of benchmark analysis for mixed contaminant exposures: Mutual adjustment of perfluoroalkylate substances associated with immunotoxicity.
    Budtz-Jørgensen E; Grandjean P
    PLoS One; 2018; 13(10):e0205388. PubMed ID: 30339706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Application of the Benchmark Dose Method to the Incidence Data for Various Pathological Findings and Its Validation Analysis].
    Inoue K; Shigeta Y; Umemura T; Nishiura H; Hirose A
    Shokuhin Eiseigaku Zasshi; 2021; 62(2):56-64. PubMed ID: 33883337
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.